Vanguard Capital Management
IKT icon

Vanguard Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Vanguard Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Buy
4,935,354
+484,689
+11% +$867K ﹤0.01% 2814
2026
Q1 		$7.48M Buy
+4,450,665
New +$7.9M ﹤0.01% 2886

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management's IKT Position: Q2 2026 in Review

Vanguard Capital Management increased its Inhibikase Therapeutics (IKT) stake by 11% in Q2 2026, buying an estimated $867K and bringing the position to 4,935,354 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #2814.

Vanguard Capital Management first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Vanguard Capital Management held 4,935,354 shares of Inhibikase Therapeutics worth $10M as of Q2 2026.
  • Vanguard Capital Management bought 484,689 Inhibikase Therapeutics shares in Q2 2026, an estimated $867K.
  • Inhibikase Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2814 holding.
  • Vanguard Capital Management first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.